Prodrugs of DP IV-inhibitors

Details Prodrugs of DP IV-inhibitors Prodrugs of DP IV-inhibitors

2006-08-01

2006-08-01

Tate, Christopher R. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S210170, C514S210190, C514S371000, C514S423000, C546S245000, C548S966000, C548S953000, C548S537000, C548S190000, C548S146000

Reexamination Certificate

active

07084120

ABSTRACT:
Prodrug compounds of unstable inhibitors of the serine peptidase dipeptidyl peptidase IV, are used in the treatment of various disorders, especially of metabolic disorders. The Prodrug compounds can be used in the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy.

REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3174901 (1965-03-01), Sterne
patent: 3879541 (1975-04-01), Kabbe et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4028402 (1977-06-01), Fischer et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 6006753 (1999-12-01), Efendic
patent: 296 075 (1991-11-01), None
patent: 19616486 (1997-10-01), None
patent: 0 658 568 (1994-12-01), None
patent: 0 708 179 (1995-10-01), None
patent: 0 995 440 (2000-04-01), None
patent: 04-288098 (1992-10-01), None
patent: 4334357 (1992-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/17767 (1991-11-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: 9529691 (1995-11-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 97/45117 (1997-12-01), None
patent: 9822494 (1998-05-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 00/01849 (2000-01-01), None
patent: WO 00/53171 (2000-09-01), None
patent: WO 01/62266 (2001-08-01), None
Tanaka et al. 1997. Suppression of Arthritis by the Inhibitors of Dipeptidyl Peptidase IV. Int. J. Immunopharac., vol. 19, No. 1, pp. 15-24, see abstract, pp. 18-19.
Augustyns et al. 1997. Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV. Eur J Med Chem, vol. 32, pp. 301-309, see abstract.
Mentlein, R., Dahms, P., Grandt, D., Kruger, R., Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 49, 133 (1993).
Amasheh, S., Wenzel, U., Weber, W.M., Clauss, W., Daniel, H., Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in Xenopus Laevis oocytes. J. Physiol. 504, 169-174 (1997).
Campbell, I.W., Sulphonylureas and metformin: efficacy and inadequacy. 3:33-51 (1990).
Mercla Index, 11thEdition, p. 934.
Martindale the Extra, Pharmacopoeia, p. 1619.
J. Lin et al.: “Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-0-hydroxylamine peptidomimetics” Proceedings of the National Academy of Sciences of USA, vol. 95, Nov. 1998.
Korom, S. et al., Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients, Transplantation vol. 63, p. 1495-1500, Nov. 10, 1997.
Tanaka, S. et al., Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int. J. Immunopharmacol. vol. 19, No. 1, p. 15-24 (1997).
Wetzl, W. et al., Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes. Neuropeptides, 31, (1), p. 41-45 (1997).
Thorens, B et al., Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM.Diabetes42:1219-1225 (1993).
Orskov C. et al., Proglucagon Products in Plasma of Noninsulin-dependent Diabetics and Nondiabetic Controls in the Fasting State and After Oral Glucose and Intravenous Argine.J. Clin. Invest.87:415-423 (1991).
Pauly, R. et al., Improved Glucagon Tolerance in Rats Treated with the Dipeptidyl Peptidase IV (CD26) Inhibitor ILE-Thaxolidide.Metabolism48:385-389 (1999).
Gutniak, M. K. et al., Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM.Diabetes Care17:1039-1044, (Sep. 1994).
Chemical Abstracts, vol. 115. No. 15, (Oct. 14, 1991) Columbus, Ohio, US; abstract No. 149947q, Schoen Ekkehard et al: “Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes” Seite 37; XP002114197 Zusammenfassung & Biol. Chem. Hoppe-Seyler, Bd. 372, Nr. 5, 1991, Seiten 305-311.
Chemical Abstracts, vol. 126, No. 2, (Jan. 13, 1997) Columbus, Ohio, US; abstract No. 16161j, Stoeckel A. et al: “Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides” Seite 241; XP002114198 Zusammenfassung & Pept: Chem., Struct.Biol., Proc.Am.Pept.Symp., Nr. 14, 1995, Seiten 709-710.
Chemical Abstracts, vol. 118, No. 25, (Jun. 21, 1993) Columbus, Ohio, US; abstract No. 255342K, Seite 933; XP002114199 Zusammenfassung & JP 04 334357 A (Fujerebio Inc) (Nov. 20, 1992).
Arai, H. et al: “Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships: in vitro inhibition of prolyl endopeptidase” Chemical and Pharmaceutical Bulletin., Bd. 41, Nr. 9, 1993.
Winslow, R., Novartis Drug Alters Picture for Diabetes.Wall Street Journal,Wed. Dec. 27, 2000, p. B2.
Willms, B. et al., Gastric Emptying, Glucose Response, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients.JCEM81:327332 (1996) No. 1 327-332.
Hendrick, G.K. et al., Glucagon-Like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats.Metabolismvol. 42., No. 1, p. 1-6 (Jan. 1993).
Deacon, C. et al., Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro and N-Terminally Truncated Peptide that is a Major Endogenous Metabolite in Vivo.JCEM80:952-957, (Apr. 25, 1995).
Hoffman, T. et al., Inhibition of Dipeptidyl Peptidase IV (DPIV) by anti-DP IV antibodies and non-substrate X-X-Pro- Oligopeptides Ascertained by Capillary Electrophoresis.Journal of Chromatography A,716 355-362 (1995).
Nauck, M.A. et al., Normalization of Fasting Hyperglycaemia by Exogenous Glucagon-Like Peptide I (7-36 Amide) in Type 2 (Non-insulin-dependent) Diabetic Patients.Diabetologia36:741-744 (1993).
The Merck Index, 12thEdition, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, p. 1014.
Martindale The Extra Pharmacopoeia, 30thEdition, London Pharmaceutical Press, 1993, p. 36.
Durinx, C.; et al.; “Reference Values for Plasma Dipepidyl-Pepidase IV activity and their Association with Other Laboratory Parameters”. Clin Chem Lab Med 2001, Feb. 39 (2) : 155-9, 1 page.
Gossrau, R.; “Cytochemistry of Membrane Proteases”. Histochem J, 1985, Jul. 17 (7) :737-71, 1 page.
Hahn, T.; et al.; “Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae”. Acta Histochem 1993, Dec. 1995 (2) :185-92, 1 page.
Heymann, E.; et al.; “Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation.” Klin Wochenschr, 1984, Jan. 2;62 (1) :2-10, 1 page.
Magyar, C.E.; et al.; “Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension.” Am J Physiol Renal Physiol, 2000, Aug. 279 (2) :F358-69, 1 page.
Papies, B.; et al.; “Isoenzyme (Lactate Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension.” Cor Vasa, 1991; 33 (3) :218-26, 1 page.
Qureshi. N.U.; et al.; “Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock”. Regul Pept, Sep. 25, 1998, 75-76:215-20, 1 page.
Index Nominum, International Drug Directory 1992/1993, Medpharm Scientific Publishers, pp. 728-729.
The Merck Index, An Encyclopedia of Chemicals and Drugs, 9thEdition, Merck & Co., Inc., 1976, p. 773.
C.J. Bailey et al.,New Antidiabetic Drugs,Smith-Gordon Nishimura, 1990, p. 36.
C.B. Welch,Medical Management of Non-Insulin-Dependent(Type II)Diabetes,3rdedition, American D

Affiliated with

Also associated with

Rating

Prodrugs of DP IV-inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prodrugs of DP IV-inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs of DP IV-inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3678118